Influenza activity in Canada is increasing; six regions reporting localized activity
During week 02, influenza activity in Canada started to increase with more regions reporting localized (n=6; in ON, AB, BC & NT) and sporadic activity (n=20).The majority of regions still reported no activity (n=28) (see map). The proportion of tests that were positive for influenza continued to increase steadily with a percentage positive of 5.5% (170/3,111) this week (see table). The majority of influenza virus detections to date this season were influenza A viruses (57.4% or 335/584). In week 02, the ILI consultation rate was 16 ILI consultations per 1,000 patient visits (see ILI graph), which is below the expected range for this week. The sentinel response rate was 64%. In week 02, 5 new influenza outbreaks were reported: 3 in LTCFs (in ON, BC & NT), 1 in a hospital and 1 in a school (both from BC).
Antigenic Characterization:
Since 1 September 2008, the NML has antigenically characterized 69 influenza viruses: 16 influenza A/Brisbane/59/2007(H1N1)-like (from BC, AB, ON & NS), 2 influenza A/Brisbane/10/2007(H3N2)-like (from BC & ON), 4 influenza B/Florida/4/2006-like (from AB & ON) and 47 B/Malaysia/2506/2004-like (from QC, ON & AB). A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2) and B/Florida/4/2006 are the influenza A and influenza B components recommended for the 2008-09 influenza vaccine. B/Malaysia/2506/2004 was the influenza B component for the 2007-2008 season vaccine (see pie chart).
Antiviral Resistance:
Results from the NML:
Since the start of the season, the NML has tested 23 influenza A isolates (16 H1N1 and 7 H3N2) for amantadine resistance. All of the H1N1 isolates were susceptible; however all of the H3N2 isolates were resistant to amantadine (resistance = 100% or 7/7). The resistant isolates were from ON, AB and BC.
The NML has also tested 51 influenza isolates (15 A/H1N1, 2 A/H3N2 & 34 B) for oseltamivir (Tamiflu) resistance. All of the A/H3N2 and B isolates were sensitive; however all of the A/H1N1 isolates were resistant to oseltamivir due to the H274Y mutation (resistance = 100% or 15/15). The resistant isolates were from NS, ON, AB and BC.
All 47 influenza isolates (11 A/H1N1, 2 A/H3N2 & 34 B) tested for zanamivir resistance to date were sensitive to zanamivir.
Oseltamivir resistance findings from Provincial laboratories:
To date this season, 46 influenza isolates in BC have been sub-typed as A/H1 and were assessed genotypically for oseltamivir resistance using an SNP assay. Fourty-two isolates tested positive for the H274Y mutation (resistance = 100% or 42/42), with the other 4 specimens still pending confirmatory testing.
Influenza-associated Paediatric Hospitalizations:
In week 02, one laboratory-confirmed influenza-associated paediatric hospitalization (from QC) due to influenza A infection was reported through the Immunization Monitoring Program Active (IMPACT) network. To date, 20 hospitalizations have been reported of which half (50%) have been due to influenza A and half due to influenza B. The proportion of cases to date by age group are as follows: 15% were 0-5 month olds; 20% were 6-23 month olds; 25% were 2-4 year-olds; 15% were 5-9 year-olds; and 25% were 10-16 year-olds.
*** Due to technical difficulties with IMPACT's electronic reporting system, reports of hospitalizations were not received until this week. Over the next several weeks, more retrospective reports of cases may be reported. The first hospitalization for the 2008-2009 season occurred in late November 2008. To date, cases have been reported in QC, ON, AB & BC.
CDC: During week 01, overall influenza activity in the United States remained relatively low but increased compared to previous weeks. More states reported widespread, regional and local influenza activity compared to previous weeks. Of the 3,394 specimens tested this week for influenza viruses, 242 (7.1%) were positive. Since 1 October 2008, the CDC has antigenically characterized 158 influenza viruses: 93 influenza A(H1) (all A/Brisbane/59/2007-like), 13 A(H3) (all A/Brisbane/10/2007-like) and 52 influenza B (17 were B/Florida/04/2006-like belonging to the B/Yamagata lineage and the other 35 belonged to the B/Victoria lineage). Since 1 October, 2008, 187 influenza viruses (103 A(H1N1), 23 A (H3N2), and 61 B) have been tested for resistance to neuraminidase inhibitors. Of the A(H1N1) viruses tested, 98% (101/103) were resistant to oseltamivir however all were sensitive to zanamivir. All of the A(H3N2) and B viruses tested were sensitive to both oseltamivir and zanamivir. The CDC tested 126 influenza A viruses (103 H1, 23 H3) for amantadine resistance: only one of the H1N1 viruses was resistant to amantadine (1%, 1/103) however all the H3N2 viruses (100%) were resistant.
EISS: Influenza activity continued to intensify and spread across Europe with most countries now reporting medium to high intensity with a west-to-east spread being observed. Influenza A(H3) viruses continue to predominate. With the exception of the few B/Victoria lineage viruses, the viruses circulating in Europe are similar to the strains included in the current influenza vaccine. Of the 89 A(H3N2) isolates that were tested for adamantanes susceptibility, 88 (99%) were resistant. Of the 60 A(H1N1) virus isolates tested for resistance against neuraminidase inhibitors, 59 (98%) were resistant to oseltamivir, but all were sensitive to zanamivir.
Human Avian Influenza: Since 17 January 2009, the WHO has reported 5 new cases of human H5N1 avian influenza infection. Three cases were reported from China (all from different provinces) of which 1 died; and 2 cases were reported from Indonesia (also from different provinces) of which both died.
| Province
of reporting laboratories |
Report Period: January 11, 2009 to January 17, 2009 |
Season to Date: August 24, 2008 to January 17, 2009 |
||||||
| Total
# Influenza Tests |
# of Positive Tests | Total
# Influenza Tests |
# of Positive Tests | |||||
| Influenza A | Influenza B | Total | Influenza A | Influenza B | Total | |||
NL |
13 | 0 | 0 | 0 | 218 | 0 | 0 | 0 |
PE |
7 | 0 | 1 | 1 | 70 | 0 | 1 | 1 |
NS |
38 | 1 | 0 | 1 | 323 | 2 | 0 | 2 |
NB |
55 | 4 | 0 | 4 | 281 | 5 | 0 | 5 |
QC |
963 | 26 | 2 | 28 | 8918 | 91 | 7 | 98 |
ON |
1187 | 23 | 51 | 74 | 11296 | 67 | 169 | 236 |
MB |
59 | 0 | 1 | 1 | 998 | 0 | 2 | 2 |
SK |
191 | 2 | 0 | 2 | 1779 | 5 | 0 | 5 |
AB |
503 | 34 | 2 | 36 | 9410 | 92 | 66 | 158 |
BC |
95 | 22 | 1 | 23 | 839 | 73 | 4 | 77 |
Canada |
3111 | 112 | 58 | 170 | 34132 | 335 | 249 | 584 |
Specimens from NT, YT, and NU are sent to reference laboratories in other provinces.
Note: Cumulative data includes updates to previous weeks; due to reporting delays, the sum of weekly report totals do not add up to cumulative totals.
Abbreviations: Newfoundland/Labrador (NL), Prince Edward Island (PE), New Brunswick (NB), Nova Scotia (NS), Quebec (QC), Ontario (ON), Manitoba (MB), Saskatchewan (SK), Alberta (AB), British Columbia (BC), Yukon (YT), Northwest Territories (NT), Nunavut (NU)
Respiratory virus laboratory detections in Canada, by geographic
regions, are available weekly on the following website:
<http://www.phac-aspc.gc.ca/bid-bmi/dsd-dsm/rvdi-divr/index-eng.php>

![]()
† sub-regions within the province or territory as defined by the provincial/territorial epidemiologist. Graph may change as late returns come in.
Influenza
Activity Level by Provincial and Territorial |
||||||||||||
|
||||||||||||
Note: Influenza activity levels, as represented on this map, are assigned and reported by Provincial and Territorial Ministries of Health, based on laboratory confirmations, sentinel ILI rates (see graphs and tables) and outbreaks. Please refer to detailed definitions. For areas where no data is reported, late reports from these provinces and territories will appear on the FluWatch website. Select single maps by report week to get this updated information.
<http://dsol-smed.phac-aspc.gc.ca/dsol-smed/fluwatch/fluwatch.phtml?lang=e>
Click on the map to view provinces/territories and maps for other weeks.


![]()

{Strain characterization, number identified, per cent of total number}
NACI recommends that the trivalent vaccine for the 2008-2009 season in Canada contain
A/Brisbane/59/2007 (H1N1)-like virus; an A/Brisbane/10/2007 (H3N2)-like virus; and a B/Florida/4/2006-like virus.

![]()
Note: No data available for mean rate in previous years for weeks 19 to 39 (1996-1997 through 2002-2003 seasons).

![]()
Please note that the above graphs may change as late returns come in.
To share this page just click on the social network icon of your choice.